CSL Limited
CSL
Classement en actions
#368
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Prix de l'action
$136.26
Capitalisation boursière
$65.39B
Changement (1 jour)
-0.61%
Changement (1 an)
-4.06%
Pays
AU
Échange CSL Limited (CSL)
Catégorie
Healthcare
EPS pour CSL Limited (CSL)
EPS au June 2026 TTM : $-5.29
Selon les derniers rapports financiers et le cours de l'action de CSL Limited, l’EPS actuel de la société (TTM) est de $-5.29. À la fin de 2024, la société avait un EPS de $5.47 une augmentation par rapport à celui de 2023, qui était de $4.55.
Historique de l'EPS de CSL Limited de 2000 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $-5.29 | -185.32% |
| 2025 | $6.20 | 13.35% |
| 2024 | $5.47 | 20.22% |
| 2023 | $4.55 | -31.37% |
| 2022 | $6.63 | 26.05% |
| 2021 | $5.26 | 13.61% |
| 2020 | $4.63 | 9.20% |
| 2019 | $4.24 | 50.89% |
| 2018 | $2.81 | -4.42% |
| 2017 | $2.94 | 9.29% |
| 2016 | $2.69 | -7.88% |
| 2015 | $2.92 | 8.15% |
| 2014 | $2.70 | 21.09% |
| 2013 | $2.23 | 12.45% |
| 2012 | $1.98 | -0.58% |
| 2011 | $1.99 | 49.05% |
| 2010 | $1.34 | 6.70% |
| 2009 | $1.25 | 7.16% |
| 2008 | $1.17 | 64.09% |
| 2007 | $0.71 | 500.34% |
| 2006 | $0.12 | -78.01% |
| 2005 | $0.54 | 168.22% |
| 2004 | $0.20 | 202.40% |
| 2003 | $0.07 | -21.18% |
| 2002 | $0.08 | -5.06% |
| 2001 | $0.09 | 83.13% |
| 2000 | $0.05 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | -427.41% |
US
|
|
| $-7.98 | 50.85% |
US
|
|
| - | - |
CH
|
|
| $27.74 | -624.39% |
NL
|
|
| $13.70 | -358.98% |
BE
|
